Aarti Drugs
Ticker > Company >

Aarti Drugs share price

Aarti Drugs Ltd.

NSE: AARTIDRUGS BSE: 524348 SECTOR: Pharmaceuticals & Drugs  166k   930   225

422.95
-5.30 (-1.24%)
NSE: Today, 10:34 AM

Price Summary

Today's High

₹ 429.6

Today's Low

₹ 419.55

52 Week High

₹ 635

52 Week Low

₹ 424.35

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 3860.26 Cr.

Enterprise Value

₹ 4329.3 Cr.

No. of Shares

9.13 Cr.

P/E

30.87

P/B

3.33

Face Value

₹ 10

Div. Yield

0.23 %

Book Value (TTM)

₹  127.02

CASH

₹ 3.82 Cr.

DEBT

₹ 472.85 Cr.

Promoter Holding

55.64 %

EPS (TTM)

₹  13.7

Sales Growth

-9.25%

ROE

12.39 %

ROCE

13.7%

Profit Growth

-7.15 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-9.25%
3 Year5.79%
5 Year9.28%

Profit Growth

1 Year-7.15%
3 Year-18.04%
5 Year10.21%

ROE%

1 Year12.39%
3 Year16.11%
5 Year21.38%

ROCE %

1 Year13.7%
3 Year16.63%
5 Year20.91%

Debt/Equity

0.4024

Price to Cash Flow

11.45

Interest Cover Ratio

6.7965

CFO/PAT (5 Yr. Avg.)

1.00673031594346

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 55.64 0.00
Jun 2024 55.67 0.00
Mar 2024 57.13 0.00
Dec 2023 57.47 0.00
Sep 2023 58.56 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has a good cash flow management; CFO/PAT stands at 1.00673031594346.
  • The company has a high promoter holding of 55.64%.

 Limitations

  • The company has shown a poor profit growth of -18.0407372739959% for the Past 3 years.
  • The company has shown a poor revenue growth of 5.78643251336355% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 577.54 538.21 559.53 492.96 543.09
Total Expenditure 512.12 478.47 490.47 438.74 483.55
Operating Profit 65.42 59.74 69.06 54.22 59.54
Other Income 0.74 1.68 1.11 0.11 0.38
Interest 7.55 6.75 8.09 7.46 7.17
Depreciation 11.78 11.8 12.34 11.71 11.86
Exceptional Items 0 0 0 0 0
Profit Before Tax 46.83 42.87 49.74 35.16 40.89
Tax 12.25 11.25 13.6 8.25 10.5
Profit After Tax 34.58 31.62 36.14 26.91 30.39
Adjusted EPS (Rs) 3.76 3.44 3.93 2.93 3.33

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1634.92 1914.89 2251.17 2497.97 2266.91
Total Expenditure 1386.98 1510.52 1930.01 2211.92 1997.74
Operating Profit 247.95 404.37 321.17 286.05 269.18
Other Income 1.06 6.42 4.77 2.23 4.18
Interest 35.74 25.71 23.05 36.18 33.21
Depreciation 46.67 47.6 47.39 47.29 47.67
Exceptional Items 8.38 0.22 0 0 0
Profit Before Tax 174.97 337.71 255.5 204.81 192.48
Tax 39.3 80 60.5 52 50.6
Net Profit 135.67 257.71 195 152.81 141.88
Adjusted EPS (Rs.) 14.56 27.65 21.06 16.5 15.43

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 23.3 93.2 92.6 92.6 91.94
Total Reserves 598.49 766.41 879.57 1021.7 1083.27
Borrowings 176.28 147.56 118.33 161.89 238.26
Other N/C liabilities 118.14 107.94 89.34 71.91 73.56
Current liabilities 554.49 521.89 854.68 847.39 684.6
Total Liabilities 1470.7 1637.01 2034.52 2195.5 2171.62
Assets
Net Block 611.57 630.52 649.41 634.48 722.29
Capital WIP 10.96 15.95 59.62 160.75 221.62
Intangible WIP 0 0 0 0 0
Investments 20.38 24.32 28.03 28.62 29.97
Loans & Advances 2.42 6.09 24.26 22.11 16.71
Other N/C Assets 0 0 0 0 0
Current Assets 825.36 960.13 1273.19 1349.53 1181.02
Total Assets 1470.7 1637.01 2034.52 2195.5 2171.62
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 174.97 337.71 255.5 204.81 192.48
Adjustment 79.82 65.35 66.76 78.43 77.69
Changes in Assets & Liabilities -21.34 -161.11 -202.27 -66.71 118.17
Tax Paid -37.32 -87.78 -80.09 -54.83 -51.23
Operating Cash Flow 196.15 154.18 39.9 161.7 337.1
Investing Cash Flow -29.35 -69.03 -125.36 -131.14 -187.09
Financing Cash Flow -167.76 -85.28 84.11 -30.54 -148.81
Net Cash Flow -0.96 -0.13 -1.35 0.03 1.2

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 58.56 57.47 57.13 55.67 55.64
aarnav rashesh gogri 0.20 0.20 0.20 0.20 0.20
aarti life science llp 0.01 0.01 0.01 0.01 0.01
aashay rashesh gogri 0.96 0.96 0.96 0.96 0.96
aashyav business trust (a... 1.50 1.50 1.50 1.50 1.50
adhish p. patil 1.24 1.24 1.24 1.24 1.24
alchemie financial servic... 0.04 0.04 0.04 0.04 0.04
alchemie finserv pvt. ltd... 2.21 2.21 2.21 2.21 2.21
anushakti enterprise priv... 2.62 2.62 2.62 2.62 2.62
arati tushar sankhe 0.19 0.19 0.19 0.19 0.19
arti rajendra gogri 0.22 0.22 0.22 0.15 0.15
arun moreshwar patil 0.08 0.08 0.08 0.08 0.08
bhoomi harshit savla - 1.09 1.09 1.09 1.09
chandrakant vallabhaji go... 1.87 1.87 1.87 1.87 1.87
dilesh roadlines pvt ltd 0.54 0.54 0.54 0.54 0.54
gogri finserv pvt. ltd. 3.80 3.80 3.80 3.80 3.80
harshit m. savla (huf) (k... 0.01 0.01 0.01 0.01 0.01
harshit manilal savla 4.74 4.74 4.74 4.74 4.74
hetal gogri gala 3.06 3.06 3.06 3.06 3.05
hriman savla 0.02 0.02 0.02 0.02 0.02
indira madan dedhia 0.23 0.22 0.21 0.21 0.21
jay manilal savla 0.29 0.29 0.29 0.28 0.28
jaya chandrakant gogri 1.71 1.71 1.71 1.71 1.71
jigna hiren shah 0.50 0.50 0.50 0.50 0.50
kalika amit mishra 0.03 0.03 0.03 0.03 0.03
kenisha savla 0.02 0.02 0.02 0.02 0.02
manisha rashesh gogri 0.20 0.20 0.20 0.20 0.20
mirik rajendra gogri 1.79 1.31 1.31 0.80 0.80
orchid family trust (rela... 0.99 0.99 0.99 0.99 0.99
paridhi business trust (s... 0.64 0.64 0.64 0.64 0.64
prakash m. patil (huf) (k... - - 0.18 0.18 0.18
prakash moreshwar patil 9.24 9.24 9.24 9.24 9.23
priti prakash patil 4.40 4.40 4.40 4.40 4.40
rajendra vallabhaji gogri... 0.56 0.56 0.52 0.11 0.11
rashesh chandrakant gogri... 4.65 4.65 4.65 4.65 4.64
renil rajendra gogri 1.54 1.54 1.25 0.80 0.80
safechem enterprises priv... 1.22 0.61 0.61 0.61 0.61
seema harshit savla 4.93 3.84 3.84 3.84 3.84
tulip family trust (gloir... 1.01 1.01 1.01 1.01 1.01
uday moreshwar patil 0.06 0.06 0.06 0.06 0.06
vikas moreshwar patil 0.04 0.04 0.04 0.04 0.04
vishwa harshit savla 1.03 1.03 1.03 1.03 1.03
prakash m. patil (huf) (... 0.18 0.18 - - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 41.44 42.53 42.87 44.33 44.36
blend fund 2 - - - 1.22 1.14
dsp small cap fund 4.64 5.02 5.02 5.64 5.93
harit pragji shah 2.67 2.67 2.67 2.67 2.67
investor education and pr... - 0.66 0.66 - 0.67
jayshree harit shah 1.79 1.79 1.79 1.79 1.79
llp 0.10 0.08 0.10 0.08 0.10
investor education and pr... 0.66 - - 0.66 -
nikhil parimal desai 1.15 1.14 1.12 1.06 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Aarti Drugs’ arm incorporates overseas wholly owned subsidiary 28 Nov, 9:16 AM Aarti Drugs - Quaterly Results 24 Oct, 6:04 PM Aarti Drugs - Quaterly Results 24 Oct, 6:04 PM Aarti Drugs gets GMP certificate from UK MHRA 4 Oct, 11:00 AM USFDA completes inspection at Aarti Drugs’ API manufacturing facility 21 Sep, 10:08 AM USFDA issues EIR to Baddi facility of Aarti Drugs’ arm 30 Jul, 11:41 AM Aarti Drugs - Quaterly Results 26 Jul, 5:29 PM Aarti Drugs - Quaterly Results 26 Jul, 5:29 PM Aarti Drugs - Quaterly Results 26 Jul, 5:29 PM Aarti Drugs informs about conference call 19 Jul, 3:38 PM Aarti Drugs informs about compliances-certificate 10 Jul, 5:18 PM Aarti Drugs - Quaterly Results 3 May, 4:30 PM Aarti Drugs - Quaterly Results 3 May, 4:30 PM Aarti Drugs - Quaterly Results 3 May, 4:30 PM USFDA completes inspection at Baddi facility of Aarti Drugs’ arm 23 Apr, 12:47 PM Aarti Drugs - Quaterly Results 24 Jan, 4:02 PM Aarti Drugs - Quaterly Results 24 Jan, 4:02 PM Aarti Drugs - Quaterly Results 24 Jan, 4:02 PM Aarti Drugs - Quaterly Results 19 Oct, 4:00 PM Aarti Drugs - Quaterly Results 19 Oct, 4:00 PM Aarti Drugs - Quaterly Results 19 Oct, 4:00 PM Aarti Drugs informs about newspaper clipping 28 Aug, 3:20 PM Aarti Drugs - Quaterly Results 21 Jul, 4:42 PM Aarti Drugs - Quaterly Results 21 Jul, 4:42 PM Aarti Drugs - Quaterly Results 21 Jul, 4:42 PM Aarti Drugs wins Pharmexcil Outstanding Exports Awards 2021-22 7 Jul, 12:22 PM Aarti Drugs informs about disclosure 2 May, 2:58 PM Aarti Drugs - Quaterly Results 29 Apr, 6:50 PM Aarti Drugs - Quaterly Results 29 Apr, 6:50 PM Aarti Drugs informs about analyst meet 28 Feb, 4:43 PM Aarti Drugs informs about loss of share certificate 25 Feb, 10:53 AM Aarti Drugs - Quaterly Results 27 Jan, 4:43 PM Aarti Drugs - Quaterly Results 27 Jan, 4:43 PM Aarti Drugs - Quaterly Results 27 Jan, 4:43 PM Aarti Drugs informs about disclosure 27 Dec, 2:52 PM Aarti Drugs informs about loss of share certificates 28 Nov, 4:34 PM Aarti Drugs - Quaterly Results 20 Oct, 3:35 PM Aarti Drugs - Quaterly Results 20 Oct, 3:35 PM Aarti Drugs - Quaterly Results 20 Oct, 3:35 PM Aarti Drugs informs about loss of share certificate 20 Aug, 9:44 AM Aarti Drugs informs about scrutinizer's report & voting results of the AGM 5 Aug, 4:20 PM Aarti Drugs informs about proceedings of AGM 5 Aug, 9:46 AM Aarti Drugs - Quaterly Results 27 Jul, 3:55 PM Aarti Drugs - Quaterly Results 27 Jul, 3:55 PM Aarti Drugs - Quaterly Results 27 Jul, 3:55 PM Aarti Drugs informs about board meeting 21 Jul, 9:42 AM Aarti Drugs informs about loss of share certificate 14 Jun, 4:56 PM Aarti Drugs - Quaterly Results 9 May, 3:42 PM Aarti Drugs - Quaterly Results 9 May, 3:42 PM Aarti Drugs - Quaterly Results 9 May, 3:42 PM

Aarti Drugs Stock Price Analysis and Quick Research Report. Is Aarti Drugs an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Aarti Drugs and its performance over the period of time. Aarti Drugs stock price today is Rs 423.95.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Aarti Drugs cash from the operating activity was Rs 337.1041 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Aarti Drugs has a Debt to Equity ratio of 0.4024 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Aarti Drugs , the EPS growth was -6.4803 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Aarti Drugs has OPM of 11.8741252966481 % which is a bad sign for profitability.
     
  • ROE: Aarti Drugs have a average ROE of 12.3941 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Aarti Drugs is Rs 423.95. One can use valuation calculators of ticker to know if Aarti Drugs share price is undervalued or overvalued.
Last Updated on:
Brief about Aarti Drugs

Aarti Drugs Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Aarti Drugs Ltd. is a pharmaceutical company that specializes in the manufacturing and distribution of active pharmaceutical ingredients (APIs), intermediates, specialty chemicals, and pharmaceutical formulations. The company was established in XXXX and has since grown to become a prominent player in the industry.

Aarti Drugs Ltd. - Share Price

The share price of Aarti Drugs Ltd. reflects the market valuation of the company's stock. As a long-term stock investor, it is essential to analyze the company's share price trends, historical performance, and market sentiment before making any investment decisions. Our pre-built screening tools can help you analyze the stock's performance and identify potential buying or selling opportunities.

Aarti Drugs Ltd. - Balance Sheet Analysis

Analyzing the balance sheet of Aarti Drugs Ltd. can provide valuable insights into the financial health of the company. By examining the company's assets, liabilities, and shareholders' equity, investors can assess its solvency, liquidity, and overall financial stability. Our premium features, including tools such as DCF Analysis, BVPS Analysis, and DuPont analysis, can assist in calculating the fair value and evaluating the company's financial performance.

Aarti Drugs Ltd. - Annual Report

Aarti Drugs Ltd. publishes an annual report that provides a comprehensive overview of the company's operations, financial performance, and future prospects. The annual report offers insights into the company's business strategy, risk assessment, and growth initiatives. These reports are available for download on our website, allowing investors to delve deeper into the company's financials and make informed investment decisions.

Aarti Drugs Ltd. - Dividend Analysis

Analyzing the dividend history of Aarti Drugs Ltd. can be beneficial for long-term stock investors seeking income-generating opportunities. By examining the company's dividend payout ratio, dividend yield, and dividend growth rate, investors can assess the company's commitment to returning value to its shareholders. Our pre-built screening tools can assist in comparing dividend performance across multiple companies and industries.

Aarti Drugs Ltd. - Quarterly Results

Reviewing the quarterly results of Aarti Drugs Ltd. enables investors to monitor the company's performance on a more frequent basis. By analyzing key financial metrics such as revenue, net profit, and earnings per share, investors can evaluate the company's growth trajectory and profitability. Our premium features, including tools such as DCF Analysis, BVPS Analysis, and DuPont analysis, can aid in measuring the company's financial performance and determining its fair value.

Aarti Drugs Ltd. - Stock Price Analysis

Analyzing the stock price of Aarti Drugs Ltd. can provide insights into market trends, investor sentiment, and the company's growth prospects. By examining historical price data and using technical analysis tools, investors can identify potential buying or selling opportunities. Our pre-built screening tools can help investors track the stock's performance, set price alerts, and create customized watchlists.

Aarti Drugs Ltd. - Price Chart

The price chart of Aarti Drugs Ltd. showcases the historical movement of the stock's price over a specific period. By studying price patterns and trendlines, investors can gain insights into market sentiment and identify potential entry or exit points. Our pre-built screening tools provide interactive and customizable charts that can aid in technical analysis and decision-making.

Aarti Drugs Ltd. - News and Updates

Staying informed about the latest news and updates related to Aarti Drugs Ltd. is crucial for long-term stock investors. Our website provides a dedicated section for company-specific news, regulatory announcements, and market updates. By accessing reliable and timely information, investors can stay ahead of market developments and make informed investment decisions.

Aarti Drugs Ltd. - Conference Call Transcripts

Conference call transcripts offer insights into the discussions between company management and analysts during earnings calls and other important events. These transcripts provide details about the company's performance, growth strategy, and future outlook. Our website provides downloadable conference call transcripts, allowing investors to gain a deeper understanding of Aarti Drugs Ltd.'s operations and prospects.

Aarti Drugs Ltd. - Investor Presentations

Investor presentations provide a comprehensive overview of a company's business model, competitive advantages, and growth strategy. Aarti Drugs Ltd. regularly publishes investor presentations that highlight its key achievements, financial performance, and future plans. These presentations are available for download on our website, enabling investors to assess the company's investment potential and make informed decisions.

Aarti Drugs Ltd. - Promoters

The promoters of Aarti Drugs Ltd. are individuals or entities that have a significant ownership stake in the company. Promoters play a crucial role in the company's decision-making processes and long-term vision. Understanding the background and track record of the promoters can provide insights into their commitment to the company's growth and shareholder value creation.

Aarti Drugs Ltd. - Shareholders

Shareholders of Aarti Drugs Ltd. are individuals or entities that hold shares of the company's stock. Analyzing the shareholding pattern can provide insights into the company's ownership structure, institutional investor interest, and shareholder activism. Our pre-built screening tools can help investors track changes in shareholding patterns and identify significant shareholders in Aarti Drugs Ltd.

Remember, as a long-term stock investor, it is essential to conduct thorough research, evaluate the risks involved, and seek professional advice if required. Our website provides a range of tools and resources to assist you in making informed investment decisions.

Read More
X